Skip to nav Skip to content

The World of ID is At Your Fingertips

What's New

Update Alert: COVID-19: Vilobelimab

IDSA is committed to providing up-to-date guidance on COVID-19 treatment. In April 2023, the FDA granted Emergency Use Authorization for vilobelimab to treat hospitalized adults, specifically within 48 hours of starting mechanical ventilation or ECMO. This update to the 2023 guideline includes a recommendation for vilobelimab, aimed at clinicians managing critical COVID-19 cases.

View More

Latest Multimedia

Journals

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.